A Phase 1b Study to Assess the Safety, Tolerability and Antimalarial Activity of MMV533 Against Plasmodium Falciparum Blood Stage Infection in Healthy Volunteers
Latest Information Update: 04 Dec 2024
At a glance
- Drugs SAR 441121 (Primary)
- Indications Malaria
- Focus Therapeutic Use
Most Recent Events
- 03 Nov 2022 Status changed from recruiting to completed.
- 03 Aug 2022 Planned primary completion date changed from 15 Jul 2022 to 15 Sep 2022.
- 17 May 2022 Planned End Date changed from 15 Aug 2022 to 15 Sep 2022.